Project Grant HT94252311043
Award Date
9/15/23
Completion Date
9/14/27
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
West Hollywood, CA 90048, USA
Similar Awards
The U.S. Department of Defense (DoD) has awarded a $3,056,435 Project Grant to Cedars-Sinai Medical Center under the Military Medical Research and Development program (CFDA 12.420) to conduct a 4-year evaluation of short- and long-term systemic anti-tumor immunity following combined radiation and immunotherapy treatments in triple-negative breast cancer. The award, effective September 15, 2023, will support the medical center's biomedical research efforts to investigate novel therapeutic...
This $1,251,673.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Cedars-Sinai Medical Center on August 1, 2023. The grant will fund research aimed at re-engineering the intratumoral myeloid-macrophage compartment to enhance the response to radiation and immunotherapy in triple-negative breast cancer. The three-year project will be performed at Cedars-Sinai's facilities in West Hollywood, CA. As a leading...
This $4,089,970 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Cedars-Sinai Medical Center to investigate spatial reprogramming of tumor immune microenvironments through preoperative radiotherapy and immune checkpoint inhibition in HER2 negative breast cancer. The award will fund basic, translational, and clinical research over 4 years from September 2023 to August 2027 to develop new treatments,...
This Project Grant award of $1,252,479.00 from the Defense Health Agency supports Cedars-Sinai Medical Center's biomedical research to re-engineer the intratumoral myeloid-macrophage compartment and enhance the response to radiation and immunotherapy in triple-negative breast cancer. The award falls under the Military Medical Research and Development program (CFDA 12.420), which focuses on transforming health care for Service Members and the public through innovative and impactful research....
The Cedars-Sinai Medical Center will provide research services under a $3.3 million cooperative agreement award from the Department of the Army Medical Command. The award is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care. Under this four-year award beginning September 2021, Cedars-Sinai will conduct research on therapeutic targeting of breast cancer and...
The Department of Defense's Defense Health Agency awarded a $1,164,294 Project Grant to Cedars-Sinai Medical Center on September 15, 2024 under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund a 4-year project to correlate prostate-specific membrane antigen (PSMA) expression with molecular profiles in prostate cancer. Cedars-Sinai, a non-profit hospital and academic medical center, will conduct this biomedical research to advance understanding of...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $2,685,519.00 to Cedars-Sinai Medical Center in West Hollywood, CA to conduct research on "DEFINING HUMAN CORRELATES OF SUPER-EVASIVE DISSEMINATED TUMOR CELLS, THEIR PATHOLOGICAL RELEVANCE AND HOW TO ERADICATE THEM". This 4-year research project, with a performance period from July 1, 2025 to June 30, 2029, aims to advance the medical...
Cedars-Sinai Medical Center will receive $501,000 through a two-year Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support the medical center's research project "CD44 Enhances Efficacy of the Chimeric Antigen Receptor T-Cell Therapy Against Prostate Cancer." Through this funding, Cedars-Sinai researchers will investigate using CD44 to improve the effectiveness of CAR T-cell therapy in treating...
The Defense Health Agency awarded Cedars-Sinai Medical Center a $667,963 Project Grant to "INVESTIGATE EXTRACELLULAR MATRIX PROTEINS LOCAL AND SYSTEMIC ROLE IN PROMOTING SOFT TISSUE SARCOMA" over the period of 09/01/2023 to 08/30/2025. This award was made under the Military Medical Research and Development (CFDA 12.420) federal grant program, which supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public. As a...
The Department of the Army Medical Command awarded Cedars-Sinai Medical Center a $1,542,272 project grant under the Military Medical Research and Development program (CFDA 12.420) to develop targeted bioparticles for treating brain-metastatic breast cancer. The grant aims to advance an investigational drug delivery platform utilizing HER3-homing bioparticles (HPK BPs) loaded with corroles, a class of porphyrin-like compounds, to target brain metastases. Cedars-Sinai will modify its HPK protein...